Navigation Links
IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
Date:1/22/2013

NEW YORK, Jan. 22, 2013 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced that on January 17, 2013 the Company received a notice of allowance regarding its U.S. Patent Application Serial No. 13/323,030 entitled "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells." The allowed claims apply to IntelliCell's proprietary method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation. This technology is an innovative mechanical method for the separation of stromal vascular fraction without the use of enzymes. Ultrasonic cavitation is an innovative mechanical method of separating SVFCs from fat tissue. Vascular cells derived by IntelliCell's proprietary method are potentially useful in bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures.

Steven Victor MD, Chairman and CEO of IntelliCell stated, "We are very excited to receive this notice of allowance from the US Patent Office.  We believe that this is a very significant milestone for the Company and for the advancement of regenerative medicine.  The fact that we can produce viable stromal vascular fraction cells, the regenerative cells of the human body, without resorting to the use of enzymes which have the potential to effect fundamental change on the cells, is a significant step forward in the potential uses of stromal vascular fraction cells for the treatment of serious disease states and conditions.  This patent and others in process will establish IntelliCell's position as a leader in the industry focused on the minimal manipulation of human tissues to be used for regenerative procedures.  We look forward to announcing additional upcoming milestones in our continuing mission to demonstrate the safety and efficacy of our cellular treatments to the scientific, medical, and consumer stakeholder communities under guidelines established by global regulators."

Added Robert Sexauer , EVP of Clinical Development at IntelliCell; "We are very pleased to announce the claim of allowances in our US patent utilizing ultrasonic sound waves, used safely medically for decades in multiple diagnostic and therapeutic purposes, to enhance our goals in Regenerative Medicine.  The IntelliSonics™ process, developed by IntelliCell, of producing minimally manipulated therapeutically active regenerative autologous (your own) cells may make very important contributions in treating a number of disease states where no cures are available today.  We look forward to working with groups of multi-disciplinary clinicians using this promising technology."             

About IntelliCell BioSciences
IntelliCell BioSciences is a Regenerative Medicine company developing novel technologies that address the regenerative, curative and preventative conditions of disease states with high unmet clinical needs. The Company has several patent-pending applications including an industry unique method of obtaining autologous stromal vascular fraction cells (SVF) from the vasculature surrounding adipose tissue containing adult stem cells and a robust population of regenerative healing cells. The Company is also pioneering the development of autologous and allogeneic cells from living and non-living tissue donors for research purposes. IntelliCell is planning a series of in-human clinical studies with top tier universities for the treatment of osteoarthritis, multiple sclerosis, lower limb ischemic wounds, and gum regeneration in the oral cavity as well as medical aesthetics. The Company has developed a first in class cGTP cellular processing facility in New York City, purpose built and designed to be fully integrated into an ambulatory surgery center.

Investor Contact:
Jeff Ramson , CEO
ProActive Capital Group, LLC
641 Lexington Avenue, 6th Floor
New York, NY  10022
646-863-6893 office


'/>"/>
SOURCE IntelliCell BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IntelliCell BioSciences Announces FDA Registration for its Cell Processing Facility
2. IntelliCell BioSciences Files Patent Application for a New Mechanical Method to Separate Stromal Vascular Fraction from the Blood Vessels in Adipose Tissue
3. IntelliCell Announces Dr. Arnold I. Caplan Joins Scientific Advisory Board
4. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
5. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
6. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
7. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
8. Pressure BioSciences Partners with Constant Systems to Significantly Expand Product Offerings and International Distribution
9. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
10. Amarantus BioSciences Appoints Dr. Robert J. Zimmerman as Product Development Advisor
11. 3-V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
(Date:2/5/2016)... New York , February 5, 2016 ... new Transparency Market Research report states that the global ... in 2014 and is predicted to reach US$185.9 bn ... CAGR of 6.50% from 2014 to 2020. The title ... (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic ...
(Date:2/5/2016)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s largest ... dental, animal health and medical practitioners, announced today that ... majority ownership interest in Dental Cremer S.A., a distributor ... . --> ... dental distribution business of Cremer S.A. With 2015 sales ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... US Sports ... Studio in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is ... just one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... The American ... technology, such water may be safer than regular municipal or well water. The recent ... radio host Sharon Kleyne, could go a long way toward increasing public acceptance of ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Give To ... users to search for and donate to Give To Cure’s campaign that is crowdfunding ... that lets users make and share payments through a smart device. In 2015 alone, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point ... Best in KLAS: Software & Services for HIT Implementation Support & Staffing report ... independently ranks vendor performance by healthcare executives, managers and clinicians representing over 4,500 ...
(Date:2/5/2016)... ... 05, 2016 , ... Dr. Justin Scott and Dr. Lydia Muccioli of ... Day to individuals in need. The event is scheduled to take place on February ... is to provide dental care to community members in need. Each patient will be ...
Breaking Medicine News(10 mins):